YiChang HEC ChangJiang Pharmaceutical : VOLUNTARY ANNOUNCEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜 昌 東 陽 光 長 江 藥 業 股 份 有 限 公 司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

VOLUNTARY ANNOUNCEMENT

ESCITALOPRAM OXALATE TABLETS APPROVED TO LAUNCH

This announcement is made by YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the ''Company'', together with its subsidiaries, the ''Group'') on a voluntary basis.

The board of directors (the ''Board'') of the Company is pleased to announce that Escitalopram Oxalate Tablets (5mg, 10mg, 15mg and 20mg) (the ''Product'') acquired by the Company from Sunshine Lake Pharma Co., Ltd.* (廣東東陽光藥業有限公司) (''Sunshine Lake Pharma'') have undergone the assessment and approval process and obtained approval for launch from the China National Medical Products Administration. The marketing authorization holder of the Product is Dongguan Yangzhikang Pharmaceutical Co., Ltd.* (東莞市陽之康醫藥有限責任公司) (''Yangzhikang''), a wholly-owned subsidiary of the Company.

- 1 -

Escitalopram is used to treat depression and is a single dextrorotatory optical isomer of Citalopram, a bicyclic hydrogen phthalate derivative. The mechanism of Escitalopram's anti- depression may be to inhibit the reuptake of serotonin (5-HT) by neurons in the central nervous system, which is related to the enhancement of the function of central serotonergic nerves.

Escitalopram belongs to Class A (甲類品種) under the National Drug Catalog for Basic Medical Insurance, Work-Related Injury Insurance, and Maternity Insurance (國家基本醫療 保險、工傷保險和生育保險藥品目錄) (2020 version), and also a variety under the National Essential Drugs List (國家基本藥物目錄) (2018 version). According to the data from IQVIA, the sales of Escitalopram in China in 2020 was approximately USD121 million.

The Product is a generic drug which obtained the approval for launch in China. After obtaining the approval for launch, it has been deemed to have passed the generic drug quality and efficacy consistency evaluation. The Product has high clinical value and favourable market prospects and will become one of the Company's products in the field of psychiatric disorders treatment after its launch, which will further enrich the Group's product portfolio and will also provide patients with a choice of medication with high quality and fair price.

This announcement is made by the Company on a voluntary basis to keep investors informed of the latest business development of the Group, and contains no advertisement or intention regarding the use of any drug, surgical device, therapy or oral product.

On behalf of the Board

YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

TANG Xinfa

Chairman

Hubei, the PRC

19 April 2021

As at the date of this announcement, the Board consists of Mr. JIANG Juncai, Mr. WANG Danjin, Mr. CHEN Yangui and Mr. LI Shuang as executive directors; Mr. TANG Xinfa and Mr. Eddy HUANG as non-executive directors; and Mr. TANG Jianxin, Mr. ZHAO Dayao, Ms. XIANG Ling and Mr. LI Xuechen as independent non-executive directors.

• For identification purposes only

- 2 -